Pomp

One takeaway of Declare data is that this SGLT2 reduced 3 Point Mace events by 2.6 %. BOM shows only 11% of patients are on this class of medications as a SOC addition. So I believe this translates into only a 0.25% reduction in 3 Point Mace in  total and placebo BOM  population; this may be evidence that Examine indeed may be a very solid model of BOM placebo event rates ? And not skewed very much at all by improved/ newer  SOC SGLT2 medications ?